CurrentEmblemHealthPolicy N/A

Lyme Disease Intravenous Treatment

Defines medical necessity criteria, limitations, and excluded indications for IV antibiotic therapy for members with confirmed Lyme disease; applies to EmblemHealth plans and providers submitting authorization or post-payment review.

Policy Summary

PayerEmblemHealth

PolicyLyme Disease Intravenous Treatment

Policy CodePolicy N/A

Change TypeClarified — repeat/prolonged IV threshold revised

Effective DateN/A

Next Review DateN/A

Key ActionObtain preauthorization and submit clinical evidence that the member meets the medical necessity criteria for IV antibiotic therapy.

SourceLink

POLICY UPDATE CHANGES

Clarified that repeat or prolonged courses of IV antibiotics > 8 weeks (previously 4 weeks) is not considered medically necessary.

Changed policy title to 'Lyme Disease Intravenous Treatment' and transferred content to company branded template.

Added hyperlink reference to Lyme Disease Testing Reimbursement Policy for lab testing.

2-4 wksInitial IV course length

>8 wksProlonged IV courses not needed

3 moLab lookback for repeat IV

multipleAllowed IV agents

Coverage Criteria for IV Antibiotic Therapy

inv-01: Initial IV Therapy — Covered when ANY of the following are met

Members with a confirmed Lyme disease diagnosis are eligible for an initial 2-4-week course of intravenous (IV) antibiotic therapy when ANY of the following criteria are met:

Initial IV indications

Lyme arthritis that persists after failing to respond to a 4-week course of appropriate oral antibiotic therapy.
Lyme carditis with moderate to severe cardiac involvement as evidenced by any of the following: myopericarditis; first-degree heart block with PR interval >= 300 milliseconds; or second- or higher-degree atrio-ventricular block.
Neurologic involvement of Lyme disease (neuroborreliosis) as evidenced by any of the following: encephalomyelitis based on MRI imaging and CSF pleocytosis with no other cause found; meningitis confirmed by CSF lymphocytic pleocytosis; or sensory/motor radiculoneuropathy or peripheral neuropathy (weakness and/or pain in the extremities or chest).

Policy Summary

PayerEmblemHealth

PolicyLyme Disease Intravenous Treatment

Policy CodePolicy N/A

Change TypeClarified — repeat/prolonged IV threshold revised

Effective DateN/A

Next Review DateN/A

Key ActionObtain preauthorization and submit clinical evidence that the member meets the medical necessity criteria for IV antibiotic therapy.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-03: Repeat 2-4 week outpatient IV therapy — Covered when ALL are met

Repeat outpatient IV therapy (2-4 weeks) is considered medically necessary when ALL of the following are present:

Repeat IV criteria

The member has met the criteria for an initial course of intravenous antibiotic therapy, with relevant laboratory results obtained within the past 3 months.
The member has completed an initial course of appropriate intravenous antibiotic therapy.
The member has objective evidence of either relapse of infection, progression of Lyme disease organ damage, and/or the finding of a new focus or type of organ damage.

inv-04: Not medically necessary — common excluded indications (ANY)

IV therapy is not considered medically necessary for the following indications:

Excluded indications

Early Lyme disease (erythema migrans without systemic manifestations).
Flu-like syndrome (fatigue, fever, headache, mild neck stiffness, arthralgias, myalgias).
Initial treatment of Lyme arthritis.
Non-specific subjective symptoms such as persistent chronic fatigue, difficulty concentrating, musculoskeletal pain (fibromyalgia), and headache.
Pregnant women presenting with localized Lyme disease manifested as a single lesion of erythema migrans without other symptoms suggestive of disseminated disease.
Treatment of post-Lyme disease syndrome (persistent fatigue).
Individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease.
Prophylactic treatment of asymptomatic members when the sole evidence of Lyme disease is a positive immunologic test (ELISA, IFA, or Western blot).
Treatment of persistent Lyme-associated arthritis after two prior courses of antibiotic therapy.
Mild cardiac involvement (e.g., T-wave changes, transient ST-T depression).
Repeat or prolonged courses of IV antibiotics (> 8 weeks).
Non-evidence-based or listed alternative therapies: chelation; hyperbaric oxygen therapy; intravenous ascorbic acid; singlet oxygen therapy; and intravenous magnesium.

Procedure and Coding Information

Procedure Codes for infusion/administrationCPT

96365	Intravenous infusion; initial, up to 1 hour
96366	Intravenous infusion; each additional hour
96367	Intravenous infusion; additional sequential infusion of a new drug, up to 1 hour
96368	Intravenous infusion; concurrent infusion
96369	Subcutaneous infusion; initial, up to 1 hour
96370	Subcutaneous infusion; each additional hour
96371	Subcutaneous infusion; additional pump set-up
96374	Therapeutic/prophylactic/diagnostic injection; IV push, single or initial
96375	Therapeutic/prophylactic/diagnostic injection; each additional sequential IV push of a new substance
96376	Therapeutic/prophylactic/diagnostic injection; each additional sequential IV push of same substance in facility

1–10 of 12

1/2

inv-08: Initial IV course duration — 2-4 weeks (quick facts)

Initial IV course duration2-4 weeks

Applies toMembers with confirmed Lyme disease meeting initial IV criteria (e.g., persistent Lyme arthritis after failed oral therapy, Lyme carditis with moderate–severe involvement, neuroborreliosis, or pregnant women with disseminated disease)

PurposeDefined as the standard covered duration for an initial outpatient intravenous antibiotic regimen

Policy change notePolicy clarified initial/repeat IV therapy treatment course to 2–4 weeks in revision history

inv-09: Prolonged IV therapy not medically necessary threshold — > 8 weeks

Not medically necessary threshold> 8 weeks

RationaleRepeat or prolonged courses of IV antibiotics (> 8 weeks) have not been shown to improve net health outcomes and are not considered medically necessary

Revision noteDuration threshold was revised from >4 to >8 weeks in the May 9, 2025 revision

ImplicationRepeat or prolonged IV therapy beyond this threshold will be denied as not medically necessary

inv-10: Lab results lookback for repeat IV — within the past 3 months

Required lookback period for lab results when considering repeat IV therapyLab results obtained within the past 3 months

ContextOne criterion for repeat 2–4 week outpatient IV therapy is that the member has met initial IV criteria with lab results within this timeframe

UseProviders must submit relevant laboratory results dated within the previous 3 months to support repeat IV requests

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for IV antibiotic therapy for Lyme disease. Submit a preauthorization request to EmblemHealth with the clinical documentation described below before scheduling treatment.

Prior authorization required for initial and repeat outpatient IV therapy for Lyme disease when medically necessary indications are present.
Affected indications include Lyme arthritis unresponsive to 4 weeks of oral antibiotics, moderate–severe Lyme carditis, neurologic Lyme disease (neuroborreliosis) with objective findings, stage II or III disease with organ-specific manifestations, and all symptomatic pregnant women with disseminated or later-stage disease.

Documentation Required

Documentation Requirement

The treating physician or primary care provider must submit clinical evidence that the member meets the criteria for the requested IV treatment. Failure to provide required documentation will prevent EmblemHealth from properly reviewing the preauthorization request or a post-payment claim.

Documentation must accompany the preauthorization or be available for post-payment review.
If documentation is not submitted, the request may be denied or a claim may be subject to retrospective denial.

Documentation Required

Required Clinical Documentation

Clinical documentation should include items that demonstrate the member meets medical necessity criteria for IV therapy.

Relevant diagnostic data (e.g., positive Lyme serology, CSF analysis showing lymphocytic pleocytosis for meningitis, MRI findings for encephalomyelitis).
Treatment history showing failure of a 4‑week course of appropriate oral antibiotics for Lyme arthritis when applicable.
Objective evidence of organ involvement (cardiac conduction abnormalities, myopericarditis, radiculoneuropathy, documented arthritis, or other organ-specific findings).
For pregnant members, documentation of symptomatic disseminated or later-stage disease.
Laboratory results used to establish eligibility should be from within the past 3 months when applicable.

Prior Authorization

Requirements Before Repeat or Additional IV Therapy for Arthritis

Before authorization of repeat outpatient IV therapy (repeat 2–4 week course) for Lyme disease, submit documentation that the initial criteria were met and the initial IV course was completed.

Member met criteria for initial IV antibiotic therapy and had appropriate lab results obtained within the past 3 months.
Member completed the initial course of appropriate IV antibiotic therapy.
There is objective evidence of relapse, progression of organ damage, or a new focus/type of organ damage justifying repeat therapy.

Background and Clinical Context

Lyme disease can produce disseminated, organ‑specific manifestations including arthritis, cardiac involvement, and neurologic disease (neuroborreliosis). Intravenous antibiotics are reserved for confirmed cases with these serious manifestations (for example, Lyme arthritis refractory to oral therapy, moderate to severe Lyme carditis, or neurologic involvement confirmed by CSF or imaging) and for pregnant patients with disseminated disease. IV therapy is intended for defined, time‑limited courses (typically an initial 2–4 week course when criteria are met); prolonged or repeated IV regimens beyond recommended durations lack evidence of benefit and are therefore limited or excluded under the policy.

OpenPayer

Lyme Disease Intravenous Treatment

Coverage Criteria for IV Antibiotic Therapy

Procedure and Coding Information

Provider Requirements and Authorization

Background and Clinical Context

Definitions